Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,70% hepatectomy group POD 17,,0.52,cm3,0.14,0.485,MMO:0000019,magnetic resonance imaging,liver,0.0,17-24 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days),110990,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),partial hepatectomy (70 %) (for 17 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,30% hepatectomy group POD17,,0.59,cm3,0.12,0.4157,MMO:0000019,magnetic resonance imaging,liver,0.0,17-24 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days),110991,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),partial hepatectomy (30 %) (for 17 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,sham surgical group POD17,,0.56,cm3,0.13,0.4503,MMO:0000019,magnetic resonance imaging,liver,0.0,17-24 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days),110992,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),sham surgical control condition (0 %) (for 17 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,portal vein occlusion group POD17,,0.79,cm3,0.15,0.5196,MMO:0000019,magnetic resonance imaging,liver,0.0,17-24 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days),110993,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),hepatic portal vein occlusion (for 17 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,70% hepatectomy group POD 24,,1.67,cm3,0.38,1.3164,MMO:0000019,magnetic resonance imaging,liver,0.0,17-31 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days),110994,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),partial hepatectomy (70 %) (between 17 and 31 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,30% hepatectomy group POD24,,2.21,cm3,0.58,2.0092,MMO:0000019,magnetic resonance imaging,liver,0.0,17-31 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days),110995,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),partial hepatectomy (30 %) (between 17 and 31 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,sham surgical group POD24,,2.3,cm3,0.74,2.5634,MMO:0000019,magnetic resonance imaging,liver,0.0,17-31 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days),110996,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),sham surgical control condition (0 %) (between 17 and 31 days)
3191,"Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7.",liver integrity trait,,RS:0001792,BDIX/OrlCrl,male,0 days,12,,CMO:0003757,increase in liver tumorous lesion volume between two points in time,,portal vein occlusion group POD24,,3.09,cm3,0.62,2.1477,MMO:0000019,magnetic resonance imaging,liver,0.0,17-31 days after tumor cell injection,,,,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days),110997,DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days),DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days),hepatic portal vein occlusion (between 17 and 31 days)